Xinvento, an Amsterdam, Netherlands-based biotech company, raised a Seed funding of undisclosed amount.
Backers included Ed Kaye, John Maraganore, David Meeker, Hans Schikan, James Shannon, Onno van de Stolpe, Daniel de Boer and Dinko Valerio.
The company intends to use the funds to design and test its proprietary molecules in the relevant pre-clinical models to identify potential drug candidates.
Led by CEO Claudine van der Sande, Xinvento aims to alleviate the difficulties associated with Congenital Hyperinsulinism (CHI) by developing an effective treatment to overcome the current difficulties of limited effective treatment options available to patients.
Congenital Hyperinsulinism (CHI) is a rare disease characterized by hypoglycemia (hypos) resulting from an over-secretion of insulin and is the most frequent cause of severe, random, and persistent hypos in newborns and children. Without proper and immediate treatment to prevent hypos, the patient may suffer seizures, coma, permanent brain damage, or even death.
Piet Wigerinck, a translational chemistry expert, former CSO of Galapagos, is the scientific co-founder leading the R&D efforts of the company.
FinSMEs
26/04/2022